BeOne Medicines Ltd. Q3 FY2026 earnings call

• Commercial Momentum: BRUKINSA continues to show strong fundamentals with high new patient starts, improved adherence, and sustained growth across all B-cell malignancies, not just CLL.
• Pipeline Productivity: BeOne has achieved rare late-stage productivity, advancing five solid tumor programs toward registration simultaneously, a feat typically seen only among much larger pharma companies.
• R&D Efficiency: The company leverages its 'global development superhighway' to move assets from first-in-human to pivotal trials rapidly (e.g., CDK4 inhibitor and B7-H4 ADC in 2.5 years).
• Competitive Moat: Management emphasizes a self-reinforcing feedback loop between internal research, commercial execution, and entrepreneurial culture, creating a model difficult for competitors to replicate.
• Hematology Leadership: The combination of BRUKINSA, BEQALZI, and tacabrutideg positions BeOne as the only company with potentially best-in-class medicines across three key mechanisms in B-cell malignancies.

Total revenue reached $1.9 billion, up 33% year-over-year. BRUKINSA generated $1.4 billion (74% of total revenue), growing 34%, with U.S. sales exceeding $1 billion for the first time. TEVIMBRA contributed approximately $243 million (13%), growing 28%. The Amgen in-license portfolio generated approximately $167 million (9%), growing 26%. Geographically, the U.S. was the largest market at ~$1 billion, followed by China at ~$527 million, Europe at ~$234 million, and Rest of World at ~$80 million.

• 2026 Revenue: Raised and narrowed to $6.9 billion–$7.0 billion (prior: $6.6 billion–$6.8 billion).
• 2026 Operating Expenses: Narrowed to $4.9 billion–$5.0 billion (prior: $4.8 billion–$5.0 billion).
• 2026 GAAP Operating Income: Increased expectation of $1.2 billion–$1.3 billion.
• 2026 Non-GAAP Operating Income: Increased expectation of $1.9 billion–$2.0 billion.
• Gross Margin: Maintained in the high 80s range.
• Pricing Outlook: Modest net pricing benefit expected for BRUKINSA in the remainder of 2026; however, increased Medicare Part D liability may create a flat-to-modest headwind in 2027.
• Tax Benefit: Anticipated reversal of income tax valuation allowance in Q4 2026, resulting in a material tax benefit to full-year GAAP net income.

• Biosimilar Competition: Impact from biosimilars on XGEVA is already visible within the Amgen portfolio.
• Volume-Based Procurement (VBP): Potential inclusion of XGEVA and KYPROLIS in VBP schemes poses revenue pressure risks beyond 2026.
• Regulatory Delays: FDA requested additional follow-up data for tacabrutideg, pushing the accelerated approval filing to mid-2027.
• Pricing Headwinds: Statutory increases in Medicare Part D manufacturer liability could negatively impact net pricing in 2027.

Q: Analyst asked about the timing shift for tacabrutideg filing and competitive advantages of the GPC3 x 4-1BB bispecific over BioNTech’s regimen.

A: Amit Agarwal explained that while Phase II results were positive, the FDA requested additional durability and safety follow-up for this first molecular entity, necessitating a mid-2027 filing. Mark Lanasa highlighted that the GPC3 x 4-1BB offers superior tolerability compared to cytotoxic options in liver cancer patients with compromised function, showing no CRS and durable responses, which supports earlier-line combinations with TEVIMBRA and bevacizumab.

Q: Analyst questioned the long-term ambition behind funding the RevMed RASonate 312 CRC study and future margin expansion given heavy R&D investment.

A: Lai Wang stated that conducting the study aligns with BeOne’s strategy to lead in precision oncology and explore further combinations with RevMed assets. Aaron Rosenberg clarified that while operating income will grow meaningfully, margin percentage expansion will be modest in 2027 as the company balances near-term profitability with disciplined investment in its large pipeline opportunity.

Q: Analyst asked how increasing the sample size of the CDK4 inhibitor trial accelerates readouts and about differential efficacy in CEA ADC mutants vs. wild types.

A: Mark Lanasa explained that upsizing the KANDELA-302 study increases statistical power without changing event rate assumptions, allowing enrollment of the larger cohort in the same timeframe and thus pulling in the readout date. Regarding the CEA ADC, Mark noted that while early data showed higher response rates in EGFR wild-type patients, the mutant cohort was too small to draw definitive conclusions, with more robust data expected soon.

Q: Analyst inquired about the drivers behind BRUKINSA’s recent acceleration and the impact of Pirtobrutinib’s updated frontline data.

A: Matt Shaulis attributed growth to leadership in new patient starts, real-world evidence on treatment duration, and strength in Waldenstrom’s. Amit Agarwal countered that Pirtobrutinib’s frontline data lacks differentiation against ibrutinib in safety and efficacy, particularly in elderly populations, and expressed concern that physicians are hesitant to use Pirtobrutinib upfront due to resistance mechanisms that may confer cross-resistance to covalent BTK inhibitors like BRUKINSA.